Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022
April 21, 2022 at 12:44 pm
Share
Shanxi Zhendong Pharmaceutical Co.,Ltd reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 888.84 million compared to CNY 1,293.25 million a year ago. Revenue was CNY 888.84 million compared to CNY 1,293.25 million a year ago. Net income was CNY 9.15 million compared to CNY 97.63 million a year ago. Basic earnings per share from continuing operations was CNY 0.0089 compared to CNY 0.095 a year ago. Diluted earnings per share from continuing operations was CNY 0.0089 compared to CNY 0.095 a year ago.
Shanxi Zhendong Pharmaceutical Co.,Ltd is a China-based company principally engaged in the research, development, production and sale of Chinese patent drugs, chemical raw materials and preparations. The Company's main products include anti-tumor series, cardiovascular and cerebrovascular series, anti-infection series, digestive system series, vitamin nutrition series, respiratory system series, antipyretic analgesic series and nervous system series. The Company is also involved in the cultivation of medicinal herbs, as well as the wholesale and retail of pharmaceutical products. The Company distributes its products in domestic market, with North China market as its main market.